GSK plc Sponsored ADR (GSK)
GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter
UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year guidance with 7-9% top-line growth forecasts, >10% growth in operating profit, and >10% EPS growth.
GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)
GSK's H1 2024 earnings report is strong, with healthy sales growth, solid core EPS increase, and upgraded outlook, resulting in attractive market multiples. However, the outlook still indicates that investors need to brace for a weak H2 2024, with Arexvy's sales worth watching out for after they slipped up in H1 2024. Along with the potential negative impact from further developments in Zantac trials, the expected disappointing earnings figures indicate risks to price over the coming months.
GSK plc (GSK) Q2 2024 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q2 2024 Earnings Conference Call July 31, 2024 7:00 AM ET Company Participants Nick Stone - Head, IR Emma Walmsley - CEO Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Conference Call Participants Peter Verdult - Citi Peter Welford - Jefferies James Gordon - JPMorgan Richard Parkes - BNP Paribas Graham Parry - Bank of America Merrill Lynch Tim Anderson - Wolfe Research Mark Purcell - Morgan Stanley Emily Field - Barclays Simon Baker - Redburn Atlantic Nick Stone Hello everyone. Welcome to today's call and webcast.
GSK sees £1.2bn wiped from its value as investors grumble about vaccine miss
Around £1.2 billion was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) after the drug giant's Q2 vaccine sales failed to pass muster with the City. Specifically, analysts at Shore Capital said the Shingrix, its shingles jab, "missed materially", while there was also some 'harrumphing' around the performance of its RSV inoculation, Arexvy.
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.
GSK Becomes Latest Pharma Firm To Lift Outlook
GSK (GSK) lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher.
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.97 per share a year ago.
GSK's better-than-expected results overshadowed by Zantac litigation
GSK shares fell Wednesday as investors concerns' about lawsuits surrounding the pharmaceutical giant's discontinued heartburn drug Zantac outweighed any positive impacts from its better-than-expected second-quarter results which saw it lift its full-year outlook.
GSK forecast upgrade fails to impress the market
GSK PLC (LSE:GSK, NYSE:GSK) has raised its annual earnings and sales forecasts after a strong second-quarter performance driven by cancer and HIV treatments. However, the performance singularly failed to impress the market still worried about the potential financial whack the drug giant might take from ongoing Zantac litigation as the shares opened 1.3% lower.
GSK raises annual profit and sales forecast after second quarter beat
British drugmaker GSK raised its annual earnings and sales forecasts on Wednesday and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
GSK reaches confidential settlement in Illinois
GSK PLC (LSE:GSK, NYSE:GSK) said it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court, which is part of the drug giant's long-running Zantac litigation. The UK pharma giant stressed it did not admit any liability in this settlement.
GSK's vaccine receives positive European Medicines Agency opinion
GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to extend its use to adults aged 50-59 who are at increased risk of RSV. If approved, it will be the first RSV vaccine for this age group in the EU.
